Multicentric, randomized, open-label, controlled study, of 12 months of follow-up to assess the effect in renal function of a immunosuppressive treatment based on tacrolimus minimization in combination with everolimus in patients with de novo liver transplantation.

Trial Profile

Multicentric, randomized, open-label, controlled study, of 12 months of follow-up to assess the effect in renal function of a immunosuppressive treatment based on tacrolimus minimization in combination with everolimus in patients with de novo liver transplantation.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2016

At a glance

  • Drugs Everolimus (Primary) ; Mycophenolate mofetil; Tacrolimus
  • Indications Liver transplant rejection; Renal failure
  • Focus Registrational; Therapeutic Use
  • Acronyms REDUCE
  • Sponsors Novartis
  • Most Recent Events

    • 06 May 2016 Status changed from recruiting to completed.
    • 10 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top